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Abstract
Background: Homeostasis of reactive oxygen species (ROS) in the skin is regulated by antioxidant defenses. The
inflammatory states of skin diseases which range from acute rashes to chronic conditions are related to the level of
ROS. The involvement of superoxide dismutase (SOD) in restoring the antioxidant capacity can then neutralize the
inflammatory response.
Results: We found that denatured Tat-SOD formulated in an aqueous medium could be delivered into mouse skin
and the penetration signals of Tat-SOD were detected in the epidermis and dermis. According to
immunohistochemical staining, Tat-SOD successfully suppressed inflammation induced by 12-O-
tetradecanoylphorbol-13-acetate (TPA), the expression of sodium nitroferricyanide (SNP)-induced cyclooxygenase-2
(COX-2), and the production of nitrotyrosine proteins. In nerve growth factor (NGF) induced differentiated PC12
pheochromocytoma cells, we demonstrated that the denatured Tat-SOD regained its antioxidant activity and
effectively protected PC12 cells from DNA fragmentation induced by paraquat. Using a luciferase reporter assay, the
data was shown Tat-SOD protected PC12 cells from ROS damage, through suppression of COX-2 or nuclear factor-
κB (NF-κB) activity occurred at the transcriptional level.
Conclusion: We showed that Tat-SOD inhibited SNP-induced COX-2 expression similarly to celecoxib and
prevented the formation of peroxynitrite as 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide. The results
suggest that denatured Tat-SOD solution may perform potential protein therapy for patients suffering from
disorders related to ROS.
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Background
In physiological surroundings, the skin is constantly ex-
posed to free radicals generated from external and in-
ternal circumstances. The buildup of reactive oxygen
species (ROS) in the skin is determined by numerous
antioxidant defense reactions, including both enzymatic
and non-enzymatic mechanisms that either prevent the
formation of ROS or scavenge those ROS generated.
However, inflammatory conditions which overwhelm the
antioxidant defense system can cause abnormal ROS
levels that raise oxidative stress to pathological levels,
resulting in deterioration of cells into diseased states,
ranging from acute rashes with itching and redness,
chronic syndromes like dermatitis (eczema) to psoriasis
and even burn trauma, by way of oxidative modifications
that alter biomolecular functions and structure and
dysregulate cell signaling that results in aberrant cyto-
kine release [1]. For example, acute sunburn induced
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by UV-radiation opens up vulnerable skin to attack by ex-
cessive ROS due to depletion of antioxidant defenses
[2–4]. Psoriasis, a chronic inflammatory skin disease,
was also suggested to involve unregulated ROS levels,
and its etiology is related to dysregulation of inflammatory
pathways, like nuclear factor-κB (NF-κB), mitogen-
activated protein kinase (MAPK) and JAK-STAT [5–8].
Burn injuries, a posttraumatic inflammatory condition, are
thought to involve oxygen restoration which promotes
superoxide production to exacerbate ischemic tissue injur-
ies by increasing lipid peroxidation products, conjugated
dienes, or malondialdehyde. Meanwhile, burns induce the
upregulation of inducible nitric oxide (NO) synthase
(iNOS), thus increasing the production of NO for periph-
eral vasodilatation, activation of the transcription factor
NF-κB, and responses by numerous cytokines. NO highly
reacts with superoxide anions to produce peroxynitrite, a
risky mediator of cell and tissue injury [9–11]. Reducing
oxidative stress by producing homeostasis through regu-
lating ROS levels can then neutralize the inflammatory re-
sponse [12–14].
Since the skin consists principally of a layer of vascular
connective tissue (namely, the corium or cutis vera) and
an external covering of epithelium tissue (namely, the epi-
dermis or cuticle) with the peripheral endings of many
sensory nerves, the sudoriferous, sebaceous glands and
the hair follicles, it has limited excretory and absorbing
powers. Some injuries that may affect all layers of the skin
to cause significant cell damages by the subsequent in-
flammatory response. Competent therapeutic approaches
to restore the antioxidant capacity in the skin can be
achieved by preventing the formation of ROS, strengthen-
ing endogenous antioxidant enzymatic activity, and
scavenging ROS using pharmacological or dietary supple-
ments. Superoxide dismutase (SOD, EC 1.15.1.1) catalyzes
the dismutation of superoxide and is considered a thera-
peutic protein for treating human inflammatory diseases.
In several countries, SOD (orgotein) is locally injected for
relief of sports injuries, osteoarthritis, and several inflam-
matory symptoms [15, 16]. Among available formulations
of SOD, a liposomal-encapsulated native SOD injection
was effective in treating systemic inflammatory diseases
and skin ulcer lesions, especially those from wounds and
burns [9, 17, 18]. Topical application of native Cu,Zn-
SOD was also effective against skin lesions, antipruritic ac-
tivity, and burns with skin transplantation [19, 20]. How-
ever, native SOD formulated by dissolving it in a vehicle of
petrolatum or water did not retain its activity for long pe-
riods [9, 21, 22].
Several in vivo studies by intraperitoneal injection or
oral administration of Tat-SOD indicated that the Tat-
SOD has been observed the distribution in rats and
mice, including liver, kidney, heart and brain. Topical
application on mice ears of Tat-SOD has been found to
suppress TPA-induced expression of proinflammatory
cytokines and enzymes regulated by reducing the activa-
tion of NF-κB and MAPK [23]. Increase of intracellular
SOD activity resulting in decreasing the ROS induced
damage was also reported in mammalian cells [24–27].
We previously constructed a human Cu,Zn-SOD
(SOD1) fused with a nine-amino-acid (RKKRRQRRR)
transactivator of transcription domain (Tat 49-57) of hu-
man immunodeficiency virus (HIV) type 1 in a bacterial
vector to produce a Tat-SOD recombinant protein. The
exogenous Tat-SOD, a novel modified form of SOD, ex-
hibited direct cellular transduction into undifferentiated
PC12 pheochromocytoma cells and a cellular protective
function against oxidative stress from paraquat-induced
cell death [28]. In the other study, we found that Tat-
SOD is conjugated to mesoporous silica nanoparticles
(MSNs) to form MSN-Tat-SOD. The data showed that
MSN-Tat-SOD effectively reduces cell apoptosis in HeLa
cells through an endosomal escape action [29].
The aim of the present study was to develop an effect-
ive therapy using the denatured Tat-SOD solution. We
first demonstrated that topical application of the dena-
tured Tat-SOD protein delivered in vivo into murine
skin and the data showed that Tat-SOD exhibited mul-
tiple effects of suppressing TPA-induced inflammation,
SNP-induced cyclooxygenase-2 (COX-2), and nitrotyro-
sine production. Then, we also demonstrated Tat-SOD
protein in vitro in differentiated PC12 cells suggested in-
creasing intracellular SOD activity to protect neuronal
cells from the ROS induced damage. The suppression of
COX-2 or NF-κB expression by Tat-SOD was attribut-
able to inhibition at the transcriptional level. The results
suggest that denatured Tat-SOD solution may perform
potential protein therapy for patients suffering from dis-
orders related to ROS.
Methods
Chemicals
Isopropyl-L-D-thiogalactopyranoside (IPTG) and a lu-
ciferase assay kit were purchased from Promega
(Madison, WI). Sodium nitroferricyanide (SNP), 12-O-
tetradecanoylphorbol-13-acetate (TPA), indomethacin
(Indo), and 2-phenyl-4,4,5,5-tetramethylimidazoline-1-
oxyl-3-oxide (PTIO) were purchased from Sigma (St.
Louis, MO). Ni2+-nitrilotriacetic acid (NTA) Sephar-
ose superflow was purchased from Qiagen (Valencia,
CA). Lastly, celecoxib (CELEBREX™) was from Phamacia
(Northumberland, UK).
Preparation of denatured recombinant Tat-SOD fusion
proteins
Expression and purification of recombinant Tat-SOD fu-
sion proteins were according to previous study [28, 30].
The recombinant Tat-SOD fusion proteins were purified
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under denaturing condition. To denature Tat-SOD fu-
sion proteins, harvested cells were disrupted by sonic-
ation in a phosphate buffer (300 mM NaCl, and 50 mM
NaH2PO4, pH 8) containing 8 M urea. After centrifuga-
tion, supernatants containing Tat-SOD fusion proteins
were collected and purified by Ni2+-NTA Sepharose
metal affinity resins according to the manufacturer’s in-
structions (Qiagen, Valencia, CA, USA). The purified
denature-form proteins were concentrated and the salts
were removed using Amicon® centrion (10 kDa
MWCO,Millipore, Bedford, MA, USA). The concen-
trated and desalted proteins were estimated by the Brad-
ford procedure using bovine serum albumin as a
standard. Finally, the purified denatured proteins were
dissolved in PBS containing 20 % glycerol and then ali-
quoted and stored at -80 °C.
Preparation of quantum dots conjugated with Tat-SOD
CdSe/ZnS quantum dots (560 nm; Nano Ocean Tech,
Springdale, AR) were dissolved in chloroform and mixed
with an equal volume of hydrating solution (distilled
water: ethanol = 1: 1, 10 mg/mL sodium thioglycolate,
and 2 μL ammonia). After the mixture was stirred for
1 h, the water layer was washed with the same volume
of acetone and centrifuged at 5000 rpm. The pellet was
dried and suspended in phosphate-buffered saline (PBS).
The quantity of quantum dots was determined by a
spectrophotometric method. The calculation followed
Beer’s rule with a coefficient factor of 1.7 × 105. Equal
moles of quantum dots and denatured Tat-SOD were
mixed and incubated for 1 h before cell transduction.
Cell lines and culture conditions
PC12 cells, from a rat pheochromocytoma cell line, were
obtained from American Type Culture Collection (Ma-
nassas, NJ) and cultured as recommended at 37 °C in
Dulbecco’s modified Eagle medium (DMEM; GIBCO,
Life Technologies Inc.) supplemented with 5 % heat-
inactivated fetal bovine serum (FBS; HyClone, Logan,
UT), 10 % horse serum, penicillin G (100 U/mL),
streptomycin (100 μg/mL), and L-glutamine (2 mM) in a
humidified atmosphere of 5 % CO2. Other reagents were
purchased from HyClone.
Western blot analysis
PC12 cell lysates were separated on 10 % sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE), and proteins were then electrophoretically trans-
ferred to a polyvinylidene difluoride (PVDF) membrane.
The membrane was incubated 1 h at room temperature
in blocking buffer (1× Tris-buffered saline-0.1 % Tween
20, and 5 % w/v nonfat dry milk), and then incubated
with a polyclonal anti-human Cu,Zn-SOD antibody for
16 h at 4 °C. The membrane was extensively washed and
incubated with a horseradish peroxidase-conjugated goat
anti-rabbit immunoglobulin G antibody (diluted 1:3000;
Jackson, West Grove, PA) for 1 h at room temperature.
Immunoreactive bands were visualized with an enhanced
chemiluminescence substrate kit (NEN, Boston, MA) ac-
cording to the manufacturer’s protocol.
Immunocytochemical staining for Tat-SOD expression
PC12 cells were fixed with 4 % paraformaldehyde, and
permeabilized with 0.1 % Triton X-100 in PBS. After be-
ing washed with PBS, cells were blocked in blocking buf-
fer for 1 h and then incubated with a polyclonal anti-
human Cu,Zn-SOD antibody for 16 h at 4 °C. Cells were
extensively washed and visualized with an anti-rabbit
Cy3-labeled secondary antibody at a 1: 1000 dilution for
2 h, and nuclei were counterstained with DAPI (a DNA
marker) for 5 min. Cells were analyzed with an Olympus
IX70-FLA inverted fluorescence microscope. Images
were taken using the SPOT system (Diagnostic Instru-
ments, Sterling Heights, MI).
DNA fragmentation analysis
Cells were lysed for 3 h at 50 °C in lysis buffer (50 mM
Tris–HCl, 10 mM EDTA, 0.5 % N-lauryl-sarcosine, and
0.5 mg/mL proteinase K), and then supplemented with
an RNase solution in lysis buffer for 3 h at 50 °C. DNA
was precipitated with phenol/chloroform (1: 1). DNA
samples were then separated on a 1 % agarose gel, and
visualized under UV illumination with staining.
Determination of SOD activity
SOD activities of cell lysates were measured according
to a method of Marklund [31]. The assay mixture, con-
taining 500 μL buffer (50 mM Tris-cacodylic acid buffer
at pH 8.4, 1 mM diethylenetriamine pentaacetic acid,
and 1 mM phosphate buffer at pH 7.0), 50 μL of sam-
ple, 50 μL of pyrogallol, and 400 μL of water, was mea-
sured at an optical density of 420 nm. The increase in
absorbance was measured for 3 min. SOD-specific ac-
tivity was expressed as units per milligram (U/mg) of
protein.
Inductively coupled plasma atomic emission spectroscopy
(ICP-AES)
The plasma technology used with mass spectrometry
(ICP-MS) for simultaneous trace element determin-
ation (Zn, Cu, Hg, Cd, and As) in recombinant pro-
teins was carried out as the most suitable method
[32]. The water was Milli-Q grade (>18 MΩ). Equip-
ment parameters, such as the torch position, voltages
of the ionic lenses, and also the voltage of the de-
tector and nebulization systems, were optimized and
followed the manual instructions: power of 1.5 kW;
plasma flow of 15 L/min; and auxiliary flow of 1.5 L/
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min. For calibration, a copper standard (1000 ppm,
Merck, Darmstadt, Germany) was diluted with 0.15 %
HNO3 to 0 ~ 50 ppb for use.
Circular dichroism (CD) measurements
Proteins for the CD analysis were dissolved in PBS to a
concentration of 2.5 μg/μL. CD spectra were measured
Fig. 1 Measurement of heavy metals in Tat-SOD using an ICP-AES and circular dichroism analysis of Tat-SOD. a Overexpression of the antioxidant
Cu,Zn-SOD gene in an E. coli expression system. Tat-SOD was expressed in a metal-dependent manner. b Identification the contents of copper,
zinc, and arsenate in E. coli expressed Tat-SOD by incubating with 0, 20, 40, 60 or 80 μM of arsenic ions as indicated were analyzed by ICP-AES.
c Identification the contents of copper, zinc, and mercury in E. coli expressed Tat-SOD by incubating with 0, 4, 8, 12, 16 or 20 μM of mercury ions
as indicated were analyzed by ICP-AES. d Effects of arsenate and mercury on the secondary conformation of the SOD protein using a circular
dichroism analysis (with a Jasco J-715 spectrometer)
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Fig. 2 (See legend on next page.)
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with a Jasco J-715 spectropolarimeter, and CONTIN
software was used to analyze the data. The mean residue
ellipticity was estimated from the mean residue weight,
which was calculated from the primary structure [30].
Luciferase assay for COX-2 and NF-κB promoter activities
PC12 cells were transfected with a COX-2 or NF-κB lu-
ciferase reporter plasmid using Lipofectamine 2000 (Life
Technologies Inc.) according to the manufacturer’s rec-
ommendations. At 24 h after transfection, cells were
treated with Tat-SOD (0, 0.5, 1.0, 1.5, 2.0 μM), indo-
methacin (20 μg/mL), or PTIO (50 mM) for 2 h before
the addition of TPA (50 ng/mL) or SNP (50 mM) for
4 h. Both firefly luciferase (FL) and Renilla luciferase
(RL) activities were measured using a dual luciferase re-
porter assay kit (Promega Co.). The FL activity was nor-
malized to the RL activity.
Animal treatments
All experimental procedures were designed to minimize
the total number of animals used and animal suffering
during sacrifice of animal through cervical dislocation.
All rules and regulations were followed during experi-
mentation on animals and were approved by the local
Animal Care Committee. All animal procedures were
approved by the Institutional Animal Care and Use
Committee (IACUC) of Taipei Medical University.
(protocol #LAC-2013-0293). Six or seven-week-old fe-
male ICR mice were used as the experimental animals
and purchased from the Laboratory Animal Center
(National Taiwan University, Taipei, Taiwan). Animals
were maintained in a room temperature and humidity-
controlled facility with a 12-h light/dark cycle. A day be-
fore the experiments, the dorsal side skin was shaved
using electric clippers. All samples in 0.05 mM CuCl2 and
ZnCl2 were diluted with acetone and applied using an ad-
justable pipette (1 cm in diameter). The indicated doses of
vehicle (acetone, 200 μL/site), Tat-SOD, celecoxib, or
PTIO were topically administered to the shaven back of a
mouse for 2 h, and then it was further treated with
TPA (10 nmol/200 μL/site) [33] or SNP (20 μmol/
200 μL/site) for 4 h. Finally, mice were sacrificed by
cervical dislocation, and skin samples (1 cm in
diameter) were obtained from the central dorsum of
the mice for further experiments.
Immunohistochemical (IHC) staining of COX-2 and
nitrotyrosine protein in mouse skin
Sections (4 μm) of formalin-fixed, paraffin-embedded
tissue were collected onto silcanized glass slides and
deparaffinized. For antigen retrieval, sections were boiled
in 10 mM citrate buffer (pH 6.0) for 10 min. Each sec-
tion was treated with 3 % hydrogen peroxide in metha-
nol for 15 min and incubated with 2 % normal goat
serum for 30 min. Sections were incubated with a pri-
mary polyclonal anti-COX-2 (Cayman, Ann Arbor, MI)
or polyclonal anti-nitrotyrosine (Upstate, Lake Placid,
NY) antibody. The section was developed using DAB
(HPR EnVisionTM system, Dako, Glostrup, Denmark)
and counterstained with Mayer’s hematoxylin.
Histological analysis of mouse skin
Skin samples were fixed with 4 % paraformaldehyde and
then histologically stained with hematoxylin and eosin
(H&E). Images were captured using an Olympus DP-70
camera on a Nikon ECLIPSE E800 microscope (at an
original magnification of × 200).
Statistical analysis
Experiments were repeated at least 3 times with similar
results. Statistical significance was determined using
Student’s t-test as indicated in the legend. P-values
are reported to 4 decimal points, and results are
expressed as mean ± standard error of the mean
(sem). (*P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001).
Results
Preparation of denatured recombinant Tat-SOD
The SOD protein manufactured for pharmaceutical ap-
proaches and clinical use was recently obtained through
biotechnological sources. We have developed an efficient
system to express and purify the new modified SOD pro-
tein, Tat-SOD. The constructed pQE-Tat-SOD expres-
sion plasmid containing sequences encoding SOD1, the
Tat 49–57 domain, and the His-tagged peptide was
(See figure on previous page.)
Fig. 2 Transduction of the denatured Tat-SOD protein into mouse skin and IHC staining of SNP-induced cyclooxygenase-2 (COX-2) and nitrotyrosine
protein expression. Dorsal skins of female ICR mice were treated topically with acetone (as the vehicle control) or indicated concentrations of Tat-SOD,
celecoxib, or PTIO for 2 h before SNP (20 μmol/200 μL/site) treatment for 4 h. All samples were applied to the backs of animals in 200 μL acetone using
an adjustable pipette (1 cm in diameter) and the effect of Tat-SOD on mouse skin was assayed with an IHC study. Finally, immunohistograms were
taken with an Olympus DP-70 camera on a Nikon ECLIPSE E800 microscope (at an original magnification of × 200). a His-tag staining. b COX-2 protein
staining. c Nitrotyrosine protein staining. Arrows indicate positive His-tag, COX-2, and nitrotyrosine staining which produced a brown-colored product
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transformed into E. coli JM109 and overexpressed by
adding IPTG at a final concentration of 1 mM for 1 h
[28]. The harvested protein with a specific activity of
1172 ± 229 SOD units/mg was purified by nickel Sephar-
ose and assayed according to a method by Marklund
[31]. Data in Fig. 1a show that Tat-SOD expression was
metal-ion dependent. The concentration of metal ions
for optimal SOD activity was about 0.5–1 mM of CuCl2
and ZnCl2. When CuCl2 and ZnCl2 exceeded 1 mM,
protein expression decreased due to cytotoxic tolerance.
The production of Tat-SOD was found to severely inter-
fere with cadmium ions due to substitution of zinc ions
necessary for catalytic activity inside the SOD molecule
[30]. We herein investigated the heavy metals mercury
and arsenate to the expression of SOD to evaluate how
the metals affected its activity. In Fig. 1b and c, both
mercury and arsenate ions, in the presence of CuCl2 and
ZnCl2, displaced the zinc content of SOD molecules
similar to that by cadmium ions and changed the SOD
conformation according to circular dichroism data
(Fig. 1d). Concentrations of 40 μM arsenate (III), 8 μM
mercury (II) ions, and 150 nM cadmium (II) ions signifi-
cantly inhibited SOD activity by half (IC50). This sug-
gests that during the preparation and formulation of
native SOD, some metals must be avoided. Therefore,
using a denatured form of SOD is a strategic choice for
therapy which takes advantage of reduced costs to keep it
native. Hence, Tat-SOD purified with nickel beads was
quantitated by the Bradford test and treated with 8 M urea
to denature it. We formulated the denatured Tat-SOD so-
lution in an isotonic aqueous medium for topical use.
Tat-SOD attenuated SNP- and TPA-induced stress via
cellular regulation of COX-2 and NF-κB in murine skin
For the in vivo study, we examined the transduction and
therapeutic evaluation of Tat-SOD in a murine skin
model. The denatured Tat-SOD solution (1 or 5 μM)
containing 0.05 mM CuCl2 and ZnCl2 was applied by
uniformly dripping it onto the surface of exfoliated mur-
ine skin for 2 h and then examining the skin using IHC
staining. The penetration signals of Tat-SOD were sig-
nificantly detected in the epidermis and dermis probed
with a Tat-specific antibody (Fig. 2a). Subsequently, we
evaluated whether transduced Tat-SOD played a role as
an antioxidant in vivo. Tat-SOD solution was topically
administered to the shaven backs of mice with celecoxib
(a COX-2 inhibitor) or PTIO (an SNP antagonist) for
30 min; then, animals were treated with SNP (an NO
donor) for 4 h to test the protective effect. The effective-
ness of Tat-SOD in inhibiting SNP-induced COX-2 and
protein nitration was later measured using an IHC ana-
lysis. Results (Fig. 2b, c) showed that treatment with
Fig. 3 Inhibition of the TPA-induced mouse cutaneous inflammation by Tat-SOD. H&E-stained histological sections of a mouse skin sample
obtained at indicated doses of Tat-SOD and celecoxib after a TPA (10 nmol/200 μL/site)-induced inflammatory response in mouse skin. Acetone-
treated mice were used as the control. a Vehicle, (b) TPA, (c-d) TPA/Tat-SOD, and (e, f) TPA/celecoxib
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SNP (20 μmol) significantly increased levels of COX-2
and nitrotyrosine-containing proteins (brown pigment)
in the epidermis. The pigment tone was significantly and
dose-dependently attenuated by Tat-SOD and celecoxib,
indicating that Tat-SOD effectively reduced SNP-
induced COX-2 production as well as did celecoxib in
mouse skin. Comparatively, the potency of 50 μg Tat-
SOD was almost equivalent to that of 10 mg celecoxib.
Further, Tat-SOD also successfully suppressed SNP-
induced nitrotyrosine production in mouse skin via at-
tenuating the production of ONOO- by scavenging
superoxide anions, demonstrating a detoxifying effect
compared to PTIO.
Furthermore, we evaluated whether the Tat-SOD solu-
tion still played a role as an anti-inflammatory agent.
Animals were challenged with TPA, which led to the ex-
cessive generation of ROS. Inflammation was induced by
triple topical applications of TPA (20 μmole) on exfoli-
ated murine back skin for 4 h; and later, Tat-SOD solu-
tion (1 or 5 μM) was topically administrated for 2 h.
Histological staining with H&E (Fig. 3) showed that TPA
induced the accumulation of inflammatory cells, vascular
congestion, and neutrophil accumulation in the perivas-
cular as a primary inflammatory phenomenon (Fig. 3b;
red arrows). Tat-SOD administration obviously and
dose-dependently reduced the accumulation of neutro-
phils (Fig. 3c, d; blue arrows). Celecoxib as a positive
control only showed a minor primary inflammatory
characteristic (Fig. 3e, f; yellow arrows). Results demon-
strated that Tat-SOD solution was effective in attenuat-
ing TPA-induced mouse cutaneous inflammation,
suggesting that Tat-SOD has high therapeutic benefits in
blocking skin inflammation.
Characterization of exogenous Tat-SOD function in vitro
The skin contains the peripheral endings of many of the
sensory nerves. The injuries may affect to the neuronal
cells caused by the subsequent inflammatory response.
The penetration signals of Tat-SOD were also signifi-
cantly detected in the epidermis and dermis in Fig. 2a.
Here we chose PC12 cell, embryological origin of neuro-
blastic cells which differentiate into neuron-like cells
and share properties similar to neurons, as a model to
study if the denatured Tat-SOD solution was useful for
cell protection in vitro. We induced the differentiation
of PC12 cells with NGF (50 ng/mL) and then added the
denatured Tat-SOD solution (1.5 μM) to the culture
medium for 1, 2, and 3 h. Results (Fig. 4a) demonstrated
that Tat-SOD-transduced PC12 cells grew well, which
indicates that Tat-SOD did not cause cell death or mor-
phologic changes. A penetration analysis assessed by im-
munofluorescence staining revealed that denatured Tat-
SOD was successfully transduced into PC12 cells in a
time-dependent manner (Fig. 4b). Instead of using indir-
ect SOD antibody staining, photostable fluorescent
quantum dots (QDots, 560 nm) were used to directly
observe penetration into living cells. We conjugated Tat-
SOD with thioglycolated QDots through a metal/His-tag
interaction; then, QDot-Tat-SOD was introduced to the
culture medium for 2 and 4 h. As shown in Fig. 4c,
transduction only occurred after Tat-SOD treatment in a
dose-dependent manner. With QDots only or QDots
conjugated with SOD, cells showed no fluorescence up-
take. Both results illustrated that the Tat-SOD protein
was quickly transduced into cells within 2 h with time-
dependent efficiency.
Restoration of the enzymatic activity of cells is critical
after proteins are transduced. Herein, we showed that
the transduced Tat-SOD protein regained its activity in
PC12 cells. PC12 cells were cultured with 1.5 μM of Tat-
SOD and 0, 0.05 or 0.1 mM of CuCl2 and ZnCl2 for 3 h.
Cell lysates were analyzed for SOD enzyme activity, and
Western blotting was used to determine SOD protein
levels. Results (Fig. 5a) showed that Tat-SOD co-
cultured with 0.05 or 0.1 mM CuCl2 and ZnCl2 had
higher SOD activities compared to Tat-SOD alone. The
Western blotting analysis (Fig. 5b) showed that the
addition of metal ions did not interfere with the trans-
duction efficiency. Meanwhile, native SOD could not
enter cells without the Tat-transducing peptide. Results
implied that the molecular refolding to gain activity oc-
curred inside cells by cellular machinery and involved
metal ions.
In addition to evaluating the antioxidant ability,
PC12 cells transduced with the Tat-SOD protein were
then treated with paraquat (70 mM), an intracellular
superoxide anion generator. Results (Fig. 5c) showed
that the addition of paraquat induced abundant DNA
fragmentation via cell apoptosis, and the Tat-SOD
protein prevented this fragmentation, demonstrating
that Tat-SOD effectively protected PC12 cells against at-
tack by superoxide anions. Even though NGF protects
(See figure on previous page.)
Fig. 4 Transduction efficiency of denatured Tat-SOD into differentiated PC12 cells. a Differentiated PC12 cells plated in a six-well plate were
treated with 1.5 μM of denatured TatSOD in the culture medium for 2 h. b Differentiated PC12 cells were incubated for various time intervals with
1.5 μM of denatured Tat-SOD. Then, the transduced fusion proteins in the cells were analyzed by immunofluorescence microscopy. DAPI, nuclear
staining; Cy3, SOD1 staining. c PC12 cells were incubated with quantum dots (QDot 560 nm)-conjugated Tat-SOD molecules for 2 or 4 h with
different doses of the conjugate (as indicated). Cells were later stained with DAPI. Results were observed using fluorescence microscopy with an
FITC filter
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neuronal cells from superoxide anion damage [34], ROS-
mediated apoptotic damage has also found in the differen-
tiated cells and could be diminished by the Tat-SOD
protein.
Furthermore, results of Tat-SOD inhibiting SNP-
induced COX-2 expression in vivo implied the involve-
ment of a cellular signal transduction pathway. Previous
studies revealed that abnormal expressions of NF-κB
and COX-2 play a crucial role in ROS-related diseases
[6, 8, 22, 35]. We further examined whether the inhibi-
tory mechanism of Tat-SOD was related to NF-κB and
COX-2 at the transcriptional level. We transfected re-
porter constructs containing COX-2 (Fig. 6a) and NF-κB
(Fig. 6b) promoters into differentiated PC12 cells and
measured the promoter activity with a luciferase re-
porter assay. As observed, treatment of transfected cells
with TPA or SNP significantly increased NF-κB and COX-
2 luciferase activities. When pretreated with Tat-SOD,
TPA- or SNP-stimulated luciferase activity was dose-
dependently inhibited. The addition of 0.5–2 μM Tat-SOD
suppressed COX-2 promoter activity by 60–80 % com-
pared to TPA or SNP alone. Indo and PTIO as positive
controls suppressed COX-2 promoter activities by 64 and
71 %, respectively. The same doses of Tat-SOD also inhib-
ited NF-κB promoter activities by 59–87 % after activation
with 50 ng/mL TPA and by 5–33 % after activation with
50 mM SNP. Indo and PTIO as references suppressed
NF-κB promoter activities by 52 and 66 %, respectively.
Together, these results suggest that Tat-SOD suppresses
COX-2 expression and NF-κB activity via regulating pro-
moter activities.
Discussion
Oxidative stress is defined as an impaired balance be-
tween ROS production and antioxidant defenses and is
involved in many diseases [36]. Removing ROS can be
an effective precautionary measure against pathogenesis
by exogenous SOD. SOD1, an oligomeric protein with
Cu2+ and Zn2+, has a two-domain structure: one domain
contains α-helices and the second is composed of both
α-helices and β-sheets [37]. Metal-binding sites are lo-
cated between two domains with side chains of histidine
and aspartate. In this paper, we demonstrated that the
addition of heavy metals caused the loss of zinc, result-
ing in conformational changes of α-helices and β-sheets.
It also implied that if the formulation was combined
with protective chelating agents in the ointment, such as
Na2EDTA or diethyldithiocarbamate, this would reduce
the binding of Cu2+ and Zn2+ in SOD molecules [38].
Improper vehicles such as large quantities of water or
vaselinum album also caused rapid instability of the na-
tive SOD. Therefore, the strategy of using denatured
protein makes preparation and formulation much easier
and simpler by avoiding the risk of deactivating the na-
tive form and loss of ligand metals. The intracellular de-
livery of macromolecules still remains problematic
because of the bioavailability restriction imposed by their
intrinsic poor stability, membrane permeability, and
endosomal trapping/degradation. Some experiments
demonstrated the efficacy of oral SOD supplements or
administration by subcutaneous, intravenous, intraperi-
toneal, or intramuscular injections. However, all these
routes have limitations with transducing a protein into
cells or the circulation, and almost all uses of native
SOD could be still unnecessarily true [39]. The design of
Tat-SOD contains a Tat domain (RKKRRQRRR) at the
NH2-terminus [40]. Using cell-penetrating peptides to
carry the peptides into cells was demonstrated to bypass
the barrier in animal and culture models [41]. Over 50
proteins of different sizes were reported in human or
murine cell types in vitro [42–45]. We herein illustrated
that the Tat-SOD penetrated into murine cells which
was independent of receptors and transporters [46], and
via an endosome escape mechanism [29].
In the present work, we assessed the effects of TPA on
inducing inflammation in mouse skin. Our results of
(See figure on previous page.)
Fig. 5 Denatured Tat-SOD transduced into PC12 cells retained its activity via protein refolding. PC12 cells were treated with or without Tat-SOD
(1.5 μM) and incubated in 0, 0.05 or 0.1 mM of CuCl2 and ZnCl2, for 2, 4 or 6 h, then cells were lysed. a Enzymatic assay of SOD. SOD-specific activity
was analyzed by the pyrogallol method (as described in “Materials and Methods”). b Cellular transduction of SOD by Tat-SOD. Cellular SOD protein
expression levels were analyzed by Western blotting. SOD only (without Tat-tagged) was used for the control. c Tat-SOD protected PC 12 cells from
superoxide anion attack generated by 70 mM paraquat. After treatment, DNA samples were isolated from PC12 cells and then separated on a 1 %
agarose gel. Lane 1, DNA marker; lane 2, cell only; lane 3, paraquat treatment; lane 4, Tat-SOD (1.5 μM) transduced with paraquat. Each
experiment was performed in triplicate. All columns displayed as mean ± SEM Significance was calculated compared to controls and p
values were calculated by applying Student’s t-test. For the additions of Tat-SOD, statistically very significant differences from added 0.05
or 0.1 mM metals (ZnCl2/CuCl2) compared to 0 mM metal control within 2 h (***p < 0.001; ****p < 0.0001, respectively), 4 h (**** p < 0.0001; **p < 0.01,
respectively) or 6 h (***p < 0.001; **p < 0.01, respectively); but, statistically no significant difference from 0.5 to 1.0 mM metals added (p > 0.05) within 2,
4 or 6 h. For the no additions of Tat-SOD, statistically no significant differences between added 0.05 or 0.1 mM (ZnCl2/CuCl2) metals compared to
0 mM metal control within 2 h (*p < 0.05; **p < 0.01, respectively), 4 h (ns, p > 0.05; **p < 0.01, respectively) or 6 h (***p < 0.001; **p < 0.01, respectively).
For the additions added of Tat-SOD within 2, 4 or 6 h with 0 mM metals (ZnCl2/CuCl2), statistically significant differences from 2 h compared to 4 or
6 h with no significant differences (p > 0.05), 4 h compared to 6 h with *p < 0.05; with 0.05 mM metals (ZnCl2/CuCl2), statistically significant differences
from 4 h compared to 2 or 6 h with no significant differences (p > 0.05), 2 h compared to 6 h with *p < 0.05; but, added 0.1 mM metals (ZnCl2/CuCl2)
within 2, 4 or 6 h statistically no significant differences (p > 0.05)
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Fig. 6 Effect of Tat-SOD on TPA- or SNP-induced promoter activity of cyclooxygenase-2 (COX-2) or nuclear factor–κB (NF-κB) in PC12 cells. PC12
cells were transfected with a luciferase reporter plasmid of (a) COX-2 or (b) NF-κB for 24 h, then incubated with Tat-SOD, indomethacin (Indo), or
PTIO for 2 h. After being stimulated for 4 h with TPA (50 ng/mL) or SNP (50 mM), luciferase activity was measured, and COX-2 and NF-κB activities
were expressed relative to cells treated with TPA or SNP alone. Each experiment was performed in triplicate. Data are represented as mean ± SEM.
Significance was calculated compared to controls and p values were calculated by applying Student’s t-test. For the relative COX-2 luciferase activity,
statistically significant difference at exposed to TPA (50 ng/mL) + Tat-SOD (0.5 μM) compared to TPA control (50 ng/mL) (**p < 0.01), very
significant differences at exposed to TPA (50 ng/mL) + Tat-SOD (1.0, 1.5, 2.0 μM) or Indo (20 μg/mL) compared to TPA control (50 ng/mL)
(***p < 0.001); also, statistically significant differences at exposed to SNP (50 mM) + Tat-SOD (0.5 or 1.0 μM) compared to SNP control
(50 mM) (**p < 0.01), very significant differences at exposed to SNP (50 mM) + Tat-SOD (1.5 or 2.0 μM) or PTIO (50 mM) compared to SNP
control (50 mM) (***p < 0.001). For the relative NF-κB Luciferase activity, statistically significant difference at exposed to TPA (50 ng/mL) +
Tat-SOD (0.5 or 1.0 μM) compared to TPA control (50 ng/mL) (**p < 0.01), very significant differences at exposed to TPA (50 ng/mL) + Tat-
SOD (1.5 μM) compared to TPA control (50 ng/mL) (***p < 0.001), and very significant differences at exposed to TPA (50 ng/mL) + Tat-SOD
(2.0 μM) or Indo (20 μg/mL) compared to TPA control (50 ng/mL) (****p < 0.0001); also, statistically significant differences at exposed to
SNP (50 mM) + Tat-SOD (0.5, 1.0, 1.5, 2.0 μM) compared to SNP control (50 mM) (****p < 0.0001), very significant differences at exposed to
SNP (50 mM) + PTIO (50 mM) compared to SNP control (50 mM) (***p < 0.001)
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H&E histostaining agreed with TPA-induced vascular
congestion and neutrophil accumulation in the perivascu-
lar region observed as a primary inflammatory reaction.
Tat-SOD effectively attenuated cutaneous inflammation,
suggesting that Tat-SOD affords a high therapeutic benefit
in skin disorders, such as neutrophil dermatose and cuta-
neous inflammation [47]. Similar to TPA, SNP-generated
oxidative stress induced expressions of iNOS and COX-2
and stimulated NF-κB migration associated with the deg-
radation of IκBα [48]. Our results showed that topical ad-
ministration of Tat-SOD inhibited SNP-induced COX-2
expression as well as did celecoxib. Celecoxib, a selective
COX-2 inhibitor, is widely used to treat rheumatoid arth-
ritis, psoriatic arthritis, adenomatous polyposis, and osteo-
arthritis [49, 50]. Compared to celecoxib, Tat-SOD
exhibited a similar potency in dose-dependently inhibiting
COX-2 expression through a different mechanism. For
SNP-induced upregulation of iNOS, the presence of NO
produced by reacting with superoxide anions leads to the
formation of peroxynitrites, which immediately interact
with tyrosine residues of proteins to form nitrotyrosines at
a rate of 6.7×109 M-1 s. PITO serves for a stable NO scav-
enger without affecting NOS activity and significantly in-
hibits NO biological actions. In our study, Tat-SOD
scavenged superoxide anions rather than NO, to attenuate
the formation of nitrotyrosines. This suggests that apply-
ing Tat-SOD without blocking NO’s biological activities
can prevent peroxynitrite-related diseases, such as sun-
burn erythema, contact hypersensitivity, and poly (ADP-
ribose) polymerase-mediated diseases [51].
Conclusions
In conclusion, we developed an effective therapeutic ap-
plication using the denatured Tat-SOD solution, a newly
modified form of SOD, which could overcome the
instability of native SOD formulations and side effects of
anti-inflammatory agents. Tat-SOD was efficiently deliv-
ered in vivo with restoration of biological activity in
mammalian tissues. Topical administration of Tat-SOD
solution exhibited a dual effect of suppressing the for-
mation of peroxynitrite and the expression of COX-2 in
murine skin. This success lays the groundwork for even-
tual transduction of therapeutic proteins into patients
with ROS-mediated diseases.
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